Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Melanoma and other skin tumours

3745 - Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy


20 Oct 2018


Poster Discussion session - Melanoma and other skin tumours


Clinical Research;  Immunotherapy

Tumour Site



Georgina Long


G.V. Long1, M. Milhem2, A. Amin3, C.J. Hoimes4, T. Medina5, R.M. Conry6, C. Lao7, G. Daniels8, S. Reddy9, I. Mehmi10, R.H.I. Andtbacka11, M. Barve12, M. Shaheen13, T. Tueting14, M. Chisamore15, B. Xing16, A. Candia17, E. Gamelin18, R. Janssen16, A. Ribas19

Author affiliations

  • 1 Medical Oncology, Melanoma Institute Australia, University of Sydney, 2060 - North Sydney/AU
  • 2 Medicine, University of Iowa, 52242 - Iowa City/US
  • 3 Medical Oncology, Levine Cancer Institute, NC 28204 - Charlotte/US
  • 4 Medical Oncology, Case Western Reserve University / University Hospitals, 44106 - Cleveland/US
  • 5 Medicine/medical Oncology, University of Colorado Cancer Center, Aurora/US
  • 6 Hematology And Medical Oncology, UAB School of Medicine, Alabama/US
  • 7 Medicine, University of Michigan Health System, Ann Arbor/US
  • 8 Medicine, University of California, San Diego, San Diego/US
  • 9 Medicine, Stanford University School of Medicine, Stanford/US
  • 10 Mary Babb Randolph Cancer Center, West Virginia University, Morgantown/US
  • 11 Surgical oncology, Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 12 Oncology, Mary Crowley Cancer Research, 75230 - Dallas/US
  • 13 Medicine, University of Arizona Cancer Center North, Tucson/US
  • 14 Dermatology, University Hospital Madgeburg, Madgeburg/DE
  • 15 Clinical research, Oncology, Merck & Co, Kenilworth/US
  • 16 Clinical Development, Dynavax Technologies Corporation, 94710 - Berkeley/US
  • 17 Discovery, Dynavax Technologies Corporation, 94710 - Berkeley/US
  • 18 Clinical Development, Dynavax Technologies Corporation, 94618 - Berkeley/US
  • 19 Department Of Medicine, Jonsson Comprehensive Cancer Center at UCLA, 90095-1781 - Los Angeles/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3745


SD-101 is a synthetic CpG-ODN agonist of TLR9. Pembrolizumab is a PD-1 inhibitor. SYNERGY-001/KEYNOTE-184 (DV3-MEL-01) assesses the safety and preliminary efficacy of the combination of SD-101 and pembrolizumab in unresectable stage IIIC-IV melanoma.


SD-101 was evaluated as 2 mg/lesion injected into 1-4 lesions and 1 or 8 mg/lesion injected into 1 lesion as 4 weekly doses followed by 7 doses Q3W. Pembrolizumab was administered as 200 mg IV Q3W. Scans were performed every 9 weeks. Responses were assessed per investigator using RECIST v1.1. Responses and Kaplan-Meier analyses of PFS in the ITT population were compared for patients who received ≤ 2 mg/lesion with 8 mg/lesion.


87 patients (1 mg: n=3; 2 mg: n=44; 8 mg: n=40) have been enrolled with similar baseline characteristics: median age 66 years; male: 68%; stage: IIIC=21%; IVM1a/b=52%; IVM1c=28%; LDH > ULN: 21%; treatment naïve: 71%; PD-L1 negative tumors: 49%. SD-101 safety profile comprises flu-like symptoms. Most frequent grade ≥3 treatment-related AEs were headache (8%), myalgia (7%), malaise (6%), fatigue (6%), chills (6%) and injection-site pain (7%). Immune-related AEs were reported in 17%. One unrelated death occurred in the 8 mg group. The best overall response (ORR) in the ≤ 2 mg group (n=47) was 66% (95% CI: 52, 78) (CR: 11%) and in the 8 mg group (n=40) was 48% (95% CI: 33, 63) (CR: 5%) with responses in both injected and non-injected lesions. ORR in 57 patients with baseline PD-L1 expression data was: PD-L1 positive: ≤ 2 mg=75% (12/16); 8 mg= 62% (8/13); PD-L1 negative: ≤ 2 mg=85% (11/13); 8 mg=33% (5/15); PD-L1 pending: ≤ 2 mg=44% (8/18); 8 mg = 50% (6/12). PFS was higher in the ≤ 2 mg group (median PFS: ≤ 2 mg=not reached [15.2+ months]; 8 mg=10.4 months, p = 0.034; 6 month PFS rate: ≤ 2 mg=86%; 8 mg=62%). Median follow up in this ongoing study is 4.9 months in the ≤ 2 mg group and 7.3 months in the 8 mg group. Tumor biopsies at Day 29 show increases in CD8+, cytotoxic T cells, and NK cells over baseline.


The TLR9 innate immune stimulant, SD-101, in combination with pembrolizumab is showing promising high response rates and prolonged PFS especially in patients who receive lower dose SD-101. The combination has been well tolerated.

Clinical trial identification


Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.